Optimal Neoadjuvant and Adjuvant Therapy for Triple-Positive Breast Cancer

Neoadjuvant Therapy Regimen

• The National Comprehensive Cancer Network recommends a neoadjuvant regimen combining pertuzumab, trastuzumab, and docetaxel, which achieves pathologic complete response rates of 45.8-66.2% in HER2+ disease 1
• Pertuzumab + trastuzumab + docetaxel for 4-6 cycles is recommended, with the highest pathologic complete response rate of 45.8% 1
• FEC (fluorouracil, epirubicin, cyclophosphamide) followed by pertuzumab + trastuzumab + docetaxel is an alternative option, with a pathologic complete response rate of 57.3-66.2% 1
• The NeoSphere and TRYPHAENA trials established that adding pertuzumab to trastuzumab-based neoadjuvant chemotherapy significantly increases pathologic complete response rates compared to trastuzumab alone (45.8% vs 29%, p=0.0063) 1

Surgical Management

• The National Comprehensive Cancer Network recommends that after neoadjuvant therapy response assessment, if the tumor responds adequately, lumpectomy with sentinel lymph node biopsy or axillary dissection is performed, depending on pre-treatment nodal staging 1, 4
• If there is minimal or no response or progression, mastectomy with level I/II axillary dissection is recommended 1, 4

Adjuvant HER2-Targeted Therapy

• The National Comprehensive Cancer Network recommends completing a total of 1 year of trastuzumab-based therapy, with pertuzumab continuation if node-positive at initial staging 2, 3, 5
• If there is pathologic complete response, continue trastuzumab (± pertuzumab if initially node-positive) to complete 1 year total 2, 3
• If there is residual disease present, switch to trastuzumab emtansine (T-DM1) for 14 cycles based on the KATHERINE trial showing superior outcomes with residual disease 2, 3, 5

Adjuvant Endocrine Therapy

• The National Comprehensive Cancer Network strongly prefers aromatase inhibitor therapy over tamoxifen for postmenopausal women with hormone receptor-positive disease based on superior efficacy 1, 4
• Letrozole 2.5 mg daily or anastrozole 1 mg daily for 5-10 years is recommended 1, 3

Adjuvant Radiation Therapy

• Radiation therapy decisions must be based on pre-chemotherapy tumor characteristics (cT2N0), not post-neoadjuvant pathology 2, 3, 5
• After lumpectomy, breast and regional lymph node irradiation is indicated 6, 4
• After mastectomy, post-mastectomy radiation to chest wall may be considered optional for cT2N0M0 disease, but is mandatory if 4 or more positive nodes at initial presentation 6, 2, 5

Key Pitfalls to Avoid

• Never base radiation decisions on post-neoadjuvant pathology—use pre-chemotherapy clinical stage (cT2N0) 2, 3
• Do not omit endocrine therapy with pathologic complete response—ER positivity mandates hormonal suppression 2, 3
• Monitor cardiac function rigorously during dual HER2 blockade 5